There are contraindications! Be sure to consult your doctor before taking any medication!
Tramix - Antifibrinolytic hemostatic used in severe hemorrhage.
Indication: For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.
Tramix is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tramix is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tramix is about 10 times more potent in vitro than aminocaproic acid. Tramix binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tramix in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by Tramix may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: